How melanomas avoid apoptosis

Many cancers become resistant to chemotherapeutic drugs thanks to loss of the p53 protein, which promotes cell cycle arrest and apoptosis in response to certain drugs. Metastatic melanomas are unusual in that, despite their chemoresistance, they retain functional p53. In the January 11 Nature, Soengas et al. find that these melanomas still lose the p53 pathway thanks to deletion and methylation of the p53 effector Apaf-1 (Nature 2001, 409:207-211). The Apaf-1 locus shows over 40% loss of heteroz

By | January 15, 2001

Many cancers become resistant to chemotherapeutic drugs thanks to loss of the p53 protein, which promotes cell cycle arrest and apoptosis in response to certain drugs. Metastatic melanomas are unusual in that, despite their chemoresistance, they retain functional p53. In the January 11 Nature, Soengas et al. find that these melanomas still lose the p53 pathway thanks to deletion and methylation of the p53 effector Apaf-1 (Nature 2001, 409:207-211). The Apaf-1 locus shows over 40% loss of heterozygosity in melanomas, and in these cells the remaining Apaf-1 gene is no longer expressed. Expression and chemoresistance can be reactivated by addition of either a methylation inhibitor or a functional Apaf-1 gene.

Popular Now

  1. UC Berkeley Receives CRISPR Patent in Europe
    Daily News UC Berkeley Receives CRISPR Patent in Europe

    The European Patent Office will grant patent rights over the use of CRISPR in all cell types to a University of California team, contrasting with a recent decision in the U.S.

  2. DNA Replication Errors Contribute to Cancer Risk
  3. Should Healthy People Have Their Exomes Sequenced?
    Daily News Should Healthy People Have Their Exomes Sequenced?

    With its announced launch of a whole-exome sequencing service for apparently healthy individuals, Ambry Genetics is the latest company to enter this growing market. But whether these services are useful for most people remains up for debate.  

  4. Rethinking a Cancer Drug Target
    Daily News Rethinking a Cancer Drug Target

    The results of a CRISPR-Cas9 study suggest that MELK—a protein thought to play a critical role in cancer—is not necessary for cancer cell survival.

Business Birmingham